Intravenous iron-gluconate during haemodialysis modifies plasma β2-microglobulin properties and levels | Zendy

Regina Michelis | Zendy; Shifra Sela | Zendy; Batya Kristal | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Intravenous iron-gluconate during haemodialysis modifies plasma β2-microglobulin properties and levels

Author(s) -

Regina Michelis,

Shifra Sela,

Batya Kristal

Publication year - 2005

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfh907

Subject(s) - beta 2 microglobulin , medicine , cellulose triacetate , iron deficiency , hemodialysis , dialysis , dose , isoelectric point , intravenous iron , pharmacology , chromatography , biochemistry , chemistry , membrane , anemia , enzyme

Intravenous iron replacement therapy is routinely used for correction of anaemia in patients with end-stage renal failure. Free or labile iron, present both in parenteral iron formulations and in blood of haemodialysis (HD) patients, has the potential to induce severe oxidative processes. This study evaluated the acute in vivo effect of intravenous iron administration on the oxidation of plasma beta2-microglobulin (beta2m) and on its plasma levels after HD.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research